HDAC9 and Kaposi's sarcoma: Also, and perhaps even more important, SCFA, such as sodium butyrate and valproic acid, that act as histone deacetylase (HDAC) inhibitors, can reactivate KSHV[21, 22], and therefore increased butyrate production, might promote KS tumorigenesis through lytic activation of KSHV[47].